Search

Displaying results 3901 - 3910 of 9702 in total
  1. Drug

    CTR-107

    go.drugbank.com/drugs/DB18583
    Experimental

    CTR-107 is a synthetic targeted growth factor. It is being investigated for the treatment of familial exudative vitreoretinopathy.

  2. Drug

    Zelpultide alfa

    go.drugbank.com/drugs/DB18587
    Investigational

    Zelpultide alfa is a recombinant human surfactant protein D.

  3. Drug

    FCR001

    go.drugbank.com/drugs/DB18595
    Investigational

    FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.

  4. Drug

    Sulfobutylether-beta-cyclodextrin

    go.drugbank.com/drugs/DB18607
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Sapablursen

    go.drugbank.com/drugs/DB18608
    Investigational

    Sapablursen is a synthetic 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a tri-antennary cluster of N-acetyl galactosamine (GalNAc3) sugars targeting transmembrane protease, serine

  6. Drug

    AAV9/MFSD8

    go.drugbank.com/drugs/DB18616
    Experimental

    AAV9/MFSD8 is a gene therapy developed by Neurogene Inc.

  7. Drug

    WU-CART-007

    go.drugbank.com/drugs/DB18617
    Investigational

    WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.

    Synonyms: an allogeneic, fratricide-resistant genetically modified T cell transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7
  8. Drug

    AB-201

    go.drugbank.com/drugs/DB18629
    Investigational

    AB-201 is a CAR-NK cell therapy targeted against HER2.[L48340] It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.

    Synonyms: Ex vivo expanded allogeneic cord blood-derived NK cells that have been genetically modified to express a HER2-directed CAR and secrete IL-15
  9. Drug

    AVR-RD-05

    go.drugbank.com/drugs/DB18631
    Experimental

    AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced _ex vivo_ with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme.

    Synonyms: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
  10. Drug

    OTL-102

    go.drugbank.com/drugs/DB18642
    Experimental

    OTL-102 consists of autologous CD34+ enriched cells that contain hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene.

    Synonyms: Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene